US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, ...

For decades, gynecologic cancer treatment has used aggressive surgical intervention and chemotherapy. These methods often ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

A new University of British Columbia-led study is shedding light on a long-overlooked consequence of colorectal cancer: the ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Ovarian cancer can affect fertility, but with timely intervention and advanced preservation methods, women of childbearing ...